HSBC upgraded Dr. Reddy’s Laboratories Limited (NYSE:RDY) from Buy to Hold, raising the price target to INR1,445 from ...

HSBC upgraded Dr Reddy’s Laboratories to Buy from Hold and raised its target price to INR 1445, citing expectations that sales of semaglutide, a generic version of Novo Nordisk’s blockbuster ...

Dr. Reddy's had announced that it has signed a collaboration agreement with Alvotech to co-develop the biosimilar candidate ...

Fintel reports that on June 5, 2025, HSBC upgraded their outlook for Dr. Reddy's Laboratories Limited - Depositary Receipt () ...

RY posts a 6.9% y/y rise in Q2 earnings as revenues climb, but higher expenses and credit provisions weigh on the results.

Royal Bank of Canada (TSX:RY) (NYSE:RY) posted its second-quarter results last week, which came in strong but also hinted at ...

Dr Reddy's announced a strategic partnership with Alvotech to develop a biosimilar to Keytruda, a top-selling cancer therapy ...

Shipments of ammonium perchlorate are expected to reach Iran in coming months and could fuel hundreds of ballistic missiles, the people said. Some of the material would likely be sent to militias in ...

The Indian banking regulator is signalling possible rule changes ahead that would let foreigners own more of India's banks, ...

Dr. Reddy’s Laboratories shares rose 4% to Rs 1303.45 against previous close of Rs 1252.15 on BSE. Market cap of the firm ...

HSBC Holdings PLC HSBC is set to deploy $4 billion into its private credit funds to drive profits higher. Nicolas Moreau, CEO ...

Shares of Dr. Reddy’s Laboratories jumped 4 per cent to Rs 1,303, positioning it among the leading gainers on the Nifty 50.